Sécurité et efficacité de l'insuline détémir en initiation chez les patients algériens diabétiques de type 2: Résultats de l'étude A1chieve

Despite poor glycemic control, initiation of insulin therapy is often delayed in type 2 diabetes over fears of hypoglycemia and weight gain. We report the clinical safety and effectiveness of insulin detemir initiation in the Algerian subgroup of the A1 chieve study. Insulin detemir therapy was well-tolerated and associated with marked improvements in HbA1c, FPG and PPPG at Week 24 (p < 0.001). A marginal non-significant increase in overall hypoglycemia was reported with no major hypoglycemic events. Weight gain was modest (0.8 kg) and a marked improvement in lipid parameters was observed. Health-related quality of life was positively impacted.